TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06688552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioception Measurements
Description: Laser cursor-assisted angle repetition test was used for proprioception assessment. A coordinate plane with different movement angles was fixed on a wall and the person was positioned 1 meter from this wall. The laser pointer was fixed on the person's arm for shoulder proprioception measurement, 5 cm above the elbow to avoid being affected by other joints, 5 cm above the person's wrist for elbow joint proprioception and fixed on the person's second metatarsal bone for wrist proprioception.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioception Measurements
Description: Laser cursor-assisted angle repetition test was used for proprioception assessment. A coordinate plane with different movement angles was fixed on a wall and the person was positioned 1 meter from this wall. The laser pointer was fixed on the person's arm for shoulder proprioception measurement, 5 cm above the elbow to avoid being affected by other joints, 5 cm above the person's wrist for elbow joint proprioception and fixed on the person's second metatarsal bone for wrist proprioception.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Measurement
Description: Myoton PRO® (Myoton AS, Tallinn, Estonia) muscle palpation device was used to assess fatigue, and the dynamic stiffness parameter was taken as the basis. The stiffness value is calculated as the maximum acceleration (N/m) of oscillation and deformation in the tissue sensed by the transducer (Chen et al., 2017). The increase in muscle dynamic stiffness has been associated with fatigue level (Klich et al., 2019; Shitova et al., 2020; Wang, 2017). Before the measurement, the athletes' pectoralis major, deltoideus and triceps brachii muscle reference points were determined and marked, and measurements were taken over these points. The athletes were asked to keep their muscles relaxed throughout the measurement in order not to affect the tissue stiffness and the application was performed at room temperature.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Measurement
Description: Myoton PRO® (Myoton AS, Tallinn, Estonia) muscle palpation device was used to assess fatigue, and the dynamic stiffness parameter was taken as the basis. The stiffness value is calculated as the maximum acceleration (N/m) of oscillation and deformation in the tissue sensed by the transducer (Chen et al., 2017). The increase in muscle dynamic stiffness has been associated with fatigue level (Klich et al., 2019; Shitova et al., 2020; Wang, 2017). Before the measurement, the athletes' pectoralis major, deltoideus and triceps brachii muscle reference points were determined and marked, and measurements were taken over these points. The athletes were asked to keep their muscles relaxed throughout the measurement in order not to affect the tissue stiffness and the application was performed at room temperature.
Study: NCT05952323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach-back
Description: According to the prepared educational materials for medical devices, students will be trained using the teach-back method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-assisted teaching
Description: Students will be sent educational videos related to medical devices and asked to watch them.
Study: NCT06694623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apically positioned flap
Description: The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apically positioned flap with FGG strip
Description: The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures. FGG strip was sutured to the apical end of recipient bed.
Study: NCT06395415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EQUIP
Description: The intervention is delivered directly to participants' mobile phones using the Insight® platform, which allows for the implementation of assessments and interventions. Insight has been used in prior mHealth studies and allows for the delivery of tailored content based on parameters, such as intervention stage. The intervention has two stages: 1) Motivational enhancement (weeks 1-2) and 2) Skills and information (weeks 3-6). The first stage of messages will utilize personalized feedback and motivational interviewing prompts, while the second stage will provide health information on ENDS and skills, such as deep breathing. Content is tailored to motivation level (low/medium or high) and dual use status.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Those in the standard advice group will be given offered a sample of NRT, instruction on its use, and will be encouraged to use in conjunction with standard web-based resources on ENDS and cessation over the course of a ten minute walk-through with study staff.
Study: NCT06022588

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Exercise + breath test
Description: The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise + breath test
Description: The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
Study: NCT04733456

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, \*EQ5D-5L, \*GAD-774, \*PHQ-975, \*PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, \*Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy

Intervention type: DEVICE
Intervention: NIRS
Description: A TechEn NIRSOptix continuous-wave fNIRS system will be used to record changes in cerebral oxygenation, at a sampling rate of 25 Hz

Intervention type: OTHER
Intervention: Stool Collection
Description: For assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome

Intervention type: OTHER
Intervention: Blood and urine collection
Description: for inflammatory markers and metabolomic \[IMC\] analysis
Study: NCT05465863

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
Description: When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
Study: NCT05779735

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasound measurements of AOP
Description: The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head
Study: NCT04609111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aspirin
Description: 1-month prasugrel monotherapy followed by clopidogrel monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-month DAPT
Description: 1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
Study: NCT05188391

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Deltoid Gap Sign
Description: At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Deltoid Gap Sign
Description: At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
Study: NCT06347679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma diffuser with single-note sweet orange essential oil
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note sweet orange essential oil into the aroma diffuser reservoir containing 120 ml of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma diffuser with single-note tea tree essential oil
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note tea tree essential oil into the aroma diffuser reservoir containing 120 ml of water.
Study: NCT00928460

Intervention type: PROCEDURE
Intervention: Removal of preoperative electrocardiogram
Description: A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
Study: NCT06559553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor+pegaspargase+dexamethasone
Description: Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
Study: NCT05947266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an adaptation of the iENGAGE
Description: Haitian immigrant iENGAGE (H-iENGAGE) is an adaptation of the iENGAGE intervention culturally adapted for Haitian immigrants with HIV that will be tested in a quasi-experimental pilot for preliminary efficacy among recently diagnosed or nonvirally suppressed adults across two Federally Qualified Health Centers (FQHCs) in Miami.
Study: NCT06347679

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aroma diffuser with water
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of water.
Study: NCT05808283

Intervention type: OTHER
Intervention: preoperative anemia frequency
Description: patients who applied to the outpatient clinic prospectively for 3 months

Intervention type: OTHER
Intervention: preoperative anemia frequency
Description: patients who applied to the outpatient clinic prospectively for 3 months
Study: NCT06151184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: 6 weeks of chiropractic care, with frequency and type of procedures determined by field clinician after initial examination.
Study: NCT04934280

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: sonohysterography
Description: saline infusion transvaginally followed by 2D transvaginal ultrasound imaging
Study: NCT04924803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No video
Description: Weekly text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Text
Description: Weekly text messages including links to intervention videos
Study: NCT06084598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986446
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06345664

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostics and intervention recommendations
Description: All families get the same diagnostics and receive individual treatment recommendations.
Study: NCT05609812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Once weekly subcutaneous (SC) injections by prefilled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT06515028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group GA
Description: Anesthesia induction will be performed preoxygenation with 3 minutes of 80% FiO2 , followed by intravenosus propofol 2-2.5 mg/kg and fentanyl 2 µg/kg. Rocuronium 0.6 mg/kg will be administered for neuromuscular blockade, followed by endotracheal intubation after 2 minutes of mask ventilation. Anesthesia maintenance will be achieved with inhalation of 2.5-3.3% sevoflurane with 50% oxygen and 50% air mixture, along with infusion of remifentanil at 0.1 micrograms/kg/min. ventilation will be performed using a volume-controlled.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group IB
Description: infraclavicular brachial plexus block will be performed in supine position with the arm adducted and flexed at 90 degrees. A mixture consisting of 15 ml of 0.5% Bupivacaine, 15 ml of 2% Lidocaine, and 30 ml of saline solution will be prepared, with equal concentrations distributed into three different syringes of 20 milliliters each. The clavicular notch will be palpated, and an ultrasound linear probe covered with a sterile sheath will be positioned in the lateral sagittal plane over this area to visualize the median, lateral, and posterior cords of the brachial plexus surrounding the axillary artery. A special Stimuplex A 22G, 100 mm needle will be used for plexus anesthesia. local anesthetic injection will be sequentially performed around the posterior, median, and lateral cords under ultrasound guidance. After confirming sensory and motor block, the operation will be commenced.
Study: NCT05475782

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spyglass-guided lithotripsy
Description: Spyglass-guided lithotripsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESWL
Description: ESWL+ERCP
Study: NCT05076370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD Day 1
Description: CBD 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD Day 2
Description: CBD 800mg
Study: NCT04951063

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation immunotherapy
Description: Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
Study: NCT05076370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD Day 3
Description: CBD 1200mg
Study: NCT06058455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDEA3 Sexual Assault Resistance Intervention
Description: Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS \& SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consent Workshop
Description: Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
Study: NCT05626608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical ring stimulation
Description: Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation in directional mode
Description: Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
Study: NCT05964166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph NMT Monitor
Description: TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
Study: NCT05083208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments.
Study: NCT05112185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Drinks, Healthy Futures
Description: The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
Study: NCT06019143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Attainment Scaling (GAS) with a goal inventory
Description: Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal Attainment Scaling (GAS) without inventory
Description: Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
Study: NCT06290505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure.